MenAfriVac as an Antitetanus Vaccine
Background. The group A meningococcal conjugate vaccine, PsA-TT, uses tetanus toxoid (TT) as a carrier protein (PsA-TT). TT as a carrier protein in other conjugate vaccines is known to be immunogenic and generates a robust anti-TT response.
Main Authors: | Borrow, Ray, Tang, Yuxiao, Yakubu, Ahmadu, Kulkarni, Prasad S., LaForce, F. Marc |
---|---|
Format: | Online |
Language: | English |
Published: |
Oxford University Press
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639489/ |
Similar Items
-
Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac
by: Tang, Yuxiao, et al.
Published: (2015) -
Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
by: Tapia, Milagritos D., et al.
Published: (2015) -
Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
by: Roy Chowdhury, Panchali, et al.
Published: (2015) -
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
by: Tapia, Milagritos D., et al.
Published: (2015) -
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
by: Diallo, Aldiouma, et al.
Published: (2015)